New advances in our understanding of Therapeutic Temperature Management are giving way to emerging treatment approaches.
Cincinnati, OH (PRWEB) July 25, 2007
The 1st Annual International Therapeutic Temperature Management Congress (TTM Congress) will be held in Cancun, Mexico from December 4-7, 2007. The Therapeutic Temperature Management Congress brings together a panel of experts to examine the current practices and research in therapeutic hypothermia and temperature modulation in patients.
"Induced hypothermia is being used with increasing frequency to provide protection for the brain, spinal cord and other organs against post-ischemic and post-traumatic injury," stated Dr. Kees H. Polderman, Lead Faculty for the TTM Congress 2007. "New advances in our understanding of Therapeutic Temperature Management are giving way to emerging treatment approaches."
This educational Congress will appeal to U.S. and international physicians, academicians, clinical researchers, ER/ICU/CCU nurses and other healthcare professionals involved in disease states, such as Cardiac Arrest, Stroke, Suspended Animation in Hypovolemic Shock, Multi-trauma, Neonatal Encephalopathy, Infection, TBI, Intra-cranial Pressure, and more. Congressional attendees will learn how the use of Therapeutic Temperature Management can provide greater benefits for patient outcomes. This program is directed toward healthcare professionals interested in reviewing the most recent clinical trial data and treatment through therapeutic hypothermia and temperature modulation in patients.
Cincinnati Sub-Zero, a platinum sponsor, will be participating in the event along with select vendors specializing in the therapeutic areas covered in the program.
"The TTM Congress will present a unique opportunity for the industry to interact with clinicians that are driving exciting new applications in temperature management. Due to limited space, only a limited number of vendors will be allowed to participate in this event. The opportunity to have meaningful dialog with clinicians that are driving new temperature management protocols is one that shouldn't be missed," stated Mark Beran, Vice President and General Manager, Cincinnati Sub-Zero, Medical Division.
More information on the TTM Congress can be found at http://www.ttmcongress.com. Information can also be obtained by contacting Watermark Research Partners at 888.457.1818.
About Therapeutic Temperature Management
Many scientific and medical articles have described the usefulness of temperature modulation, such as induced hypothermia (cooling), which is designed to protect endangered cells, prevent tissue death and preserve organ function following acute events associated with severe oxygen deprivation such as stroke or cardiac arrest. Therapeutic hypothermia is believed to work by protecting critical tissues and organs (such as the brain, heart and kidneys) following ischemic or inflammatory events, by lowering metabolism and preserving cellular energy stores, thereby potentially stabilizing cellular structure and preventing or reducing injuries at the cellular, tissue and organ level.
The American Heart Association (AHA) recently revised its treatment guidelines to recommend the use of therapeutic cooling as part of the critical care procedures for patients with an out-of-hospital cardiac arrest following ventricular fibrillation. Also, the International Liaison Committee on Resuscitation (ILCOR) has issued guidelines recommending that cardiac arrest victims be treated with induced hypothermia.
About Cincinnati Sub-Zero, Medical Division
The parent of three separate divisions, Cincinnati Sub-Zero (CSZ) is a leading manufacturer and provider of temperature management products for medical and industrial needs. CSZ is the customer-focused manufacturer of multiple therapeutic temperature control products for the healthcare market, a complete line of industrial environmental simulation testing chambers and a first-class, on-site testing laboratory.
Cincinnati Sub-Zero, Medical Division has delivered patient temperature management systems to healthcare professionals since 1963, always designed with the patient in mind. The complete line of products includes therapeutic heat therapy, cold therapy units along with a complete line of warming blankets and cooling blankets for body temperature regulation and hyper-hypothermia treatment. The Whole Body Cooling System is designed for induced clinical hypothermia and it provides an effective alternative to traditional patient cooling techniques. This revolutionary system combines a Kool Kit® (the CSZ Head Wrap, Patient Vest and custom lower body pad) and the Blanketrol® III Hypo-Hyperthermia system. In addition, CSZ recently introduced the Gelli Roll® to its line of Hyper-hypothermia pads. This unique pad combines temperature management with tissue pressure reduction and will provide unique opportunities for warming and cooling your most challenging patients. CSZ also offers a wide variety of Hypo-Hyperthermia blankets that can be utilized with the Blanketrol® line. These single-patient use or reusable blankets are designed for quick, even-temperature distribution and efficient circulation, which makes them the ideal choice for warming and cooling. Please visit http://www.cszmedical.com to learn more about CSZ, Medical Division.
About Kees H. Polderman, MD
Dr. Polderman is Vice Chairman in the Department of Intensive Care at the University Medical Center Utrecht in the Netherlands. He holds many academic and research positions. He is both a member of the Neurotrauma and Emergency Medicine Sub-committee of the European Society for Intensive Care Medicine (ESICM), and the advisory board of the journal Intensive Care Medicine. Further, he is a member of the international steering group of the Northern Hypothermia Network. He has published extensively in the field of emergency and intensive care medicine, and you will find his name on the author list of several exciting publications on the Internet (PUBMED). His current research interest is the use of therapeutic hypothermia, specifically in traumatic brain injury and after cardiopulmonary resuscitation. He has become a world-leading expert in this field. He also works as a reviewer for various international medical journals, including Intensive Care Medicine, Chest, The Lancet, Circulation, Anesthesiology, and Critical Care Medicine.
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Contact: Robin Piazza
Watermark Research Partners